Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca to close UK environmental lab

Decision on Brixham facility in Devon puts 71 positions at risk
AstraZeneca AZ Brixham Lab Devon

AstraZeneca (AZ) plans to close its environmental laboratory at Brixham in Devon having taken the decision to contract out the facility's work.

The company directly employees 71 staff at Brixham, which provides specialist services to assess the environmental impact of the pharmaceuticals and chemicals used by a range of industries.

AZ, which has been cutting back hard on staff number recently and earlier this year announced cuts of nearly 4,000 positions, said Brixham's work was “outside the organisation's strategic focus of developing innovative new medicines”.

The decision will be a bitter blow to employees, who were reassured as recently as March this year that their jobs would be safe, despite AZ's decision to downsize its UK research operations and leave Alderley Park in Cheshire for a new base in Cambridge.

Tony Broughton, head of UK operations at AstraZeneca, said: “We realise that this is difficult news for our employees at Brixham and our priority is to support them over the coming months. We also acknowledge the excellent work carried out by our people at the laboratory over its history.

“However, operating an environmental laboratory for the benefit of AstraZeneca and customers across a range of industries is not a core part of our strategy, therefore after serious consideration we propose to close the site.”

The firm is exploring “a range of options” for the site's future, Broughton said, adding AZ would like to see the lab remain in use if possible.

The historic site, which first came online in 1948 and moved to its present seafront location in 1957, started life as a testing facility for ICI Paints before being transferred to AZ-forerunner Zeneca.

The lab assesses the environmental fate and effects of chemical products and offers support for their manufacturing processes to companies in pharma and other sectors.

AZ said its plans remained subject to consultation and planning for “a responsible closure”, but the company expects its operations at the site will cease by the end of March 2014.

Article by
Dominic Tyer

25th October 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics